These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31567307)

  • 1. Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
    Rebuzzi SE; Grassi M; Catalano F; Buscaglia M; Bertulli R; Satragno C; Belgioia L; Comandini D
    Anticancer Drugs; 2020 Jan; 31(1):80-84. PubMed ID: 31567307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.
    Bernthal NM; Healey JH; Palmerini E; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Burke ZD; Geiger EJ; Spierenburg G; Laeis P; Beyerlein E; Ye X; van de Sande M
    J Surg Oncol; 2022 Dec; 126(8):1520-1532. PubMed ID: 36006054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 10. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
    Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
    Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distraction arthroplasty combined with autologous bone grafting for diffuse-type tenosynovial giant cell tumour with articular cartilage defect and subchondral bone cysts: A case report.
    Ikuta Y; Nakasa T; Sumii J; Nekomoto A; Kawabata S; Adachi N
    Mod Rheumatol Case Rep; 2023 Jun; 7(2):483-487. PubMed ID: 36484489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
    Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
    Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
    Verspoor FGM; Mastboom MJL; Hannink G; Maki RG; Wagner A; Bompas E; Desai J; Italiano A; Seddon BM; van der Graaf WTA; Blay JY; Brahmi M; Eberst L; Stacchiotti S; Mir O; van de Sande MAJ; Gelderblom H; Cassier PA
    Sci Rep; 2019 Oct; 9(1):14551. PubMed ID: 31601938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment.
    Spierenburg G; Suevos Ballesteros C; Stoel BC; Navas Cañete A; Gelderblom H; van de Sande MAJ; van Langevelde K
    Insights Imaging; 2023 Feb; 14(1):22. PubMed ID: 36725759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery.
    Griffin AM; Ferguson PC; Catton CN; Chung PW; White LM; Wunder JS; Bell RS; O'Sullivan B
    Cancer; 2012 Oct; 118(19):4901-9. PubMed ID: 22281719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark.
    Ehrenstein V; Andersen SL; Qazi I; Sankar N; Pedersen AB; Sikorski R; Acquavella JF
    J Rheumatol; 2017 Oct; 44(10):1476-1483. PubMed ID: 28765257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Tenosynovial Giant Cell Tumor of the Foot and Ankle.
    Barnett JR; Rudran B; Khan A; O'Reilly-Harbidge S; Patel S; Malhotra K; Cullen N; Welck M; Aston W
    Foot Ankle Int; 2023 Oct; 44(10):1013-1020. PubMed ID: 37644900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.